AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 23 min read$AXSM

Axsome Therapeutics Shares Rise 2.13% as Q3 Revenue Jumps 52% and Loss Narrows

Axsome Therapeutics (AXSM) reported Q3 2026 revenue of $259.7M, up 52% YoY, exceeding estimates. Loss narrowed to $0.25 per share. AUVELITY sales rose 53% to $207.6M, while SUNOSI increased 47% to $48.2M. Prescriptions for AUVELITY grew 40%. The company also updated its clinical pipeline, including Phase 3 trials for AXS-05.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 1:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Axsome Therapeutics Shares Rise 2.13% as Q3 Revenue Jumps 52% and Loss Narrows — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AXSMBullishHigh
01

Why it matters

The earnings beat underscores commercial momentum, but rising operating costs highlight cash‑flow considerations.

02

Market read

First‑report earnings surprise for a micro‑cap biotech, likely to move the stock in early trading.

03

What to watch

Upcoming Phase 3 data for AXS‑05 could add volatility regardless of the earnings beat.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Axsome Therapeutics (NASDAQ:AXSM) is a CNS‑focused biopharma with two marketed products, AUVELITY and SUNOSI.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Axsome Therapeutics reported Q3 2026 revenue of $259.7M, beating estimates and a narrower loss per share, driving a 2.13% pre‑market rise.

Expected impact

upward pressure as the market prices in the revenue beat and loss narrowing

Evidence & confidence

The surprise earnings numbers are fresh, material for a micro‑cap biotech and the stock already moved higher pre‑market.

Market effects

Sector

Strong sales of AUVELITY and SUNOSI may lift sentiment for CNS‑focused biotech peers.

Regional

U.S. biotech sector could see modest gains in early trading.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

If the higher SG&A and R&D spend erode margins, the beat may be priced out quickly.

Key entities

  • company
    Axsome Therapeutics

    Biopharma reporting Q3 2026 results.

  • product
    AUVELITY

    Depression treatment driving ~80% of revenue.

  • product
    SUNOSI

    Narcolepsy drug contributing ~19% of revenue.

Read at source← All news

StoryAxsome reports strong Q3 growth as AUVELITY sales accelerate

Also covered by

4 outlets

Related articles

NOV 2
$AXSMMedAI 8/10

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMedAI 8/10

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMed

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call

Axsome Therapeutics reported Q3 earnings, with R&D expenses rising to $50.6M and SG&A to $203.1M. AUVELITY prescriptions grew 40% YoY, while SYMBRAVO and SUNOSI also saw increases. The company expects cash to fund operations until cash-flow positivity. Axsome outlined 2027 milestones, including FDA review of AXS-12 and trials for AXS-05, solriamfetol, and AXS-20.

finance.yahoo.com2 min